KR20240161214A - T 세포 제조 조성물 및 방법 - Google Patents

T 세포 제조 조성물 및 방법 Download PDF

Info

Publication number
KR20240161214A
KR20240161214A KR1020247036158A KR20247036158A KR20240161214A KR 20240161214 A KR20240161214 A KR 20240161214A KR 1020247036158 A KR1020247036158 A KR 1020247036158A KR 20247036158 A KR20247036158 A KR 20247036158A KR 20240161214 A KR20240161214 A KR 20240161214A
Authority
KR
South Korea
Prior art keywords
cells
cell
antigen
specific
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247036158A
Other languages
English (en)
Korean (ko)
Inventor
뷰렌 메릿 엠 반
디비야 레디 렌칼라
제시카 콜러
플라비안 듀발 브라운
크리스티나 머피 쿡신
덴 베르크 요스트 휘베르트 반
보에르 레나테 드
누어 바커
톤 슈마허
Original Assignee
바이오엔테크 유에스 인크.
스티흐팅 허트 네덜란드 칸커 인스티튜트-안토니 판 레이우엔훅 지켄후이스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오엔테크 유에스 인크., 스티흐팅 허트 네덜란드 칸커 인스티튜트-안토니 판 레이우엔훅 지켄후이스 filed Critical 바이오엔테크 유에스 인크.
Publication of KR20240161214A publication Critical patent/KR20240161214A/ko
Pending legal-status Critical Current

Links

Classifications

    • A61K39/4611—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A61K39/4632—
    • A61K39/464401—
    • A61K39/46449—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
  • Moulding By Coating Moulds (AREA)
KR1020247036158A 2019-05-08 2020-05-07 T 세포 제조 조성물 및 방법 Pending KR20240161214A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962845251P 2019-05-08 2019-05-08
US62/845,251 2019-05-08
PCT/US2020/031898 WO2020227546A1 (en) 2019-05-08 2020-05-07 T cell manufacturing compositions and methods
KR1020217040167A KR102756321B1 (ko) 2019-05-08 2020-05-07 T 세포 제조 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217040167A Division KR102756321B1 (ko) 2019-05-08 2020-05-07 T 세포 제조 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20240161214A true KR20240161214A (ko) 2024-11-12

Family

ID=73051205

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247036158A Pending KR20240161214A (ko) 2019-05-08 2020-05-07 T 세포 제조 조성물 및 방법
KR1020217040167A Active KR102756321B1 (ko) 2019-05-08 2020-05-07 T 세포 제조 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217040167A Active KR102756321B1 (ko) 2019-05-08 2020-05-07 T 세포 제조 조성물 및 방법

Country Status (15)

Country Link
US (1) US12653887B2 (cg-RX-API-DMAC7.html)
EP (1) EP3965784A4 (cg-RX-API-DMAC7.html)
JP (2) JP7582971B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240161214A (cg-RX-API-DMAC7.html)
CN (2) CN121086984A (cg-RX-API-DMAC7.html)
AR (1) AR118859A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020268397A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022363A2 (cg-RX-API-DMAC7.html)
CA (1) CA3137037A1 (cg-RX-API-DMAC7.html)
IL (1) IL287874A (cg-RX-API-DMAC7.html)
MX (1) MX2021013608A (cg-RX-API-DMAC7.html)
PH (1) PH12021552829A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112346WA (cg-RX-API-DMAC7.html)
TW (2) TWI867324B (cg-RX-API-DMAC7.html)
WO (1) WO2020227546A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
WO2021178701A1 (en) * 2020-03-05 2021-09-10 Exuma Biotech Corp. Methods and compositions for the delivery of modified lymphocyte aggregates
JP7054418B2 (ja) 2017-11-08 2022-04-13 ビオンテック ユーエス インコーポレイテッド T細胞を製造する組成物及び方法
KR20210040355A (ko) * 2018-06-19 2021-04-13 바이오엔테크 유에스 인크. 네오항원 및 이의 용도
TWI867324B (zh) 2019-05-08 2024-12-21 美商百歐恩泰美國公司 T細胞製備組合物及方法
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
JP2023539056A (ja) * 2020-08-13 2023-09-13 ビオンテック ユーエス インコーポレイテッド T細胞を製造する組成物および方法
US11948694B2 (en) * 2021-05-12 2024-04-02 Merative Us L.P. Controlling compartmental flows in epidemiological modeling based on mobility data
US12062456B2 (en) 2021-05-27 2024-08-13 Merative Us L.P. Hypothetical scenario evaluation in infectious disease dynamics based on similar regions
IL312121A (en) * 2021-10-15 2024-06-01 Biontech Us Inc T cell manufacturing compositions and methods
WO2023159088A1 (en) * 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions and methods for antigen-specific t cell expansion
JP2026500232A (ja) * 2022-12-09 2026-01-06 ビオンテック ユーエス インコーポレイテッド T細胞を製造する組成物および方法
KR20240112760A (ko) * 2023-01-12 2024-07-19 주식회사 이뮤노맥스 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法
WO2025245488A2 (en) * 2024-05-24 2025-11-27 Biontech Us Inc. Compositions and methods for t cell manufacturing and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
IL106610A0 (en) 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
SG49008A1 (en) 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
EP1545610A4 (en) 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
WO2006015497A1 (en) 2004-08-13 2006-02-16 Val-Chum, S.E.C. Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors
US20060286089A1 (en) * 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
CA2643337C (en) 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with ctls and cytokines
US9809797B2 (en) * 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
WO2009106073A2 (en) 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
EP2490713A2 (en) 2009-10-23 2012-08-29 MannKind Corporation Cancer immunotherapy and method of treatment
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
SG11201404570WA (en) * 2012-02-10 2014-11-27 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
WO2015039100A1 (en) 2013-09-16 2015-03-19 The Trustees Of The University Of Pennsylvania Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
US20150104441A1 (en) 2013-10-11 2015-04-16 Oslo Universitetssykehus Hf Identification of disease-driving antigens
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
US10627411B2 (en) 2014-03-27 2020-04-21 British Columbia Cancer Agency Branch T-cell epitope identification
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
JP6661544B2 (ja) 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したt細胞の自動生成法
CN103923880B (zh) 2014-05-08 2016-03-30 成都百赛泰科生物科技有限公司 一种高效增殖、靶向杀伤肿瘤的ctl制备方法
SG11201702191YA (en) 2014-09-17 2017-04-27 Univ Johns Hopkins Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
CN107075479A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
CA3172801A1 (en) 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
DE102015214780A1 (de) * 2015-08-03 2017-02-09 Continental Automotive Gmbh Verfahren zur Erkennung fehlerhafter Komponenten eines Kraftstoffeinspritzsystems
EP3335725B1 (en) 2015-08-10 2024-02-28 Toray Industries, Inc. Pds5a epitopes as immunity inducers
KR20180043800A (ko) 2015-09-09 2018-04-30 이뮨 디자인 코포레이션 Ny-eso-1 특이적 tcrs 및 그의 사용 방법
AU2016319126A1 (en) 2015-09-10 2018-04-19 Affigen, Inc. Sequencing-directed selection of tumor theranostics
WO2017059557A1 (en) * 2015-10-09 2017-04-13 Peking University Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use
SG11201808196UA (en) 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
WO2017177337A1 (en) 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
JP7054397B2 (ja) 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用
AU2017305396A1 (en) 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
BR112020005552A2 (pt) * 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
JP7054418B2 (ja) 2017-11-08 2022-04-13 ビオンテック ユーエス インコーポレイテッド T細胞を製造する組成物及び方法
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
CA3124457A1 (en) 2018-12-21 2020-06-25 Biontech Us Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US20220282217A1 (en) 2019-03-30 2022-09-08 Biontech Us Inc. Compositions and methods for preparing t cell compositions and uses thereof
TWI867324B (zh) 2019-05-08 2024-12-21 美商百歐恩泰美國公司 T細胞製備組合物及方法
US20230398218A1 (en) 2020-08-13 2023-12-14 Biontech Us Inc. Ras neoantigens and uses thereof
JP2023539056A (ja) 2020-08-13 2023-09-13 ビオンテック ユーエス インコーポレイテッド T細胞を製造する組成物および方法
IL312121A (en) 2021-10-15 2024-06-01 Biontech Us Inc T cell manufacturing compositions and methods
JP2026500232A (ja) 2022-12-09 2026-01-06 ビオンテック ユーエス インコーポレイテッド T細胞を製造する組成物および方法

Also Published As

Publication number Publication date
KR20220044242A (ko) 2022-04-07
MX2021013608A (es) 2022-01-31
SG11202112346WA (en) 2021-12-30
WO2020227546A1 (en) 2020-11-12
CN114096261B (zh) 2025-09-26
CN114096261A (zh) 2022-02-25
JP2024038503A (ja) 2024-03-19
TWI777160B (zh) 2022-09-11
JP7855622B2 (ja) 2026-05-08
JP7582971B2 (ja) 2024-11-13
KR102756321B1 (ko) 2025-01-16
US12653887B2 (en) 2026-06-16
TW202108761A (zh) 2021-03-01
IL287874A (en) 2022-01-01
EP3965784A4 (en) 2023-06-21
JP2022531474A (ja) 2022-07-06
TW202248419A (zh) 2022-12-16
CN121086984A (zh) 2025-12-09
AU2020268397A1 (en) 2022-01-06
PH12021552829A1 (en) 2023-01-16
US20220280621A1 (en) 2022-09-08
TWI867324B (zh) 2024-12-21
CA3137037A1 (en) 2020-11-12
AR118859A1 (es) 2021-11-03
BR112021022363A2 (pt) 2022-03-22
EP3965784A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
KR102756321B1 (ko) T 세포 제조 조성물 및 방법
JP7420856B2 (ja) T細胞を製造する組成物及び方法
US20250195659A1 (en) T cell manufacturing compositions and methods
US20230374455A1 (en) T cell manufacturing compositions and methods
US20260115288A1 (en) T cell manufacturing compositions and methods
CN118574629A (zh) T细胞制备组合物和方法
HK40115457A (en) T cell manufacturing compositions and methods
HK40071072A (en) T cell manufacturing compositions and methods
HK40071072B (en) T cell manufacturing compositions and methods

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241029

Application number text: 1020217040167

Filing date: 20211207

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241121

Comment text: Request for Examination of Application